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Summary Mitozolomide is a novel antitumour agent showing a broad spectrum of activity against murine
tumours and is currently undergoing Phase I clinical evaluation in the UK. We have conducted an animal
pharmacokinetic study using male BALB/c mice as a pre-requisite to the clinical work. Mice were dosed i.p.
at 5 dose levels (0.25-20mgkg-1) and the oral and transdermal routes of administration were investigated at
20 mgkg-1. The analytical data produced a good fit to a simple open one-compartment pharmacokinetic
model with an elimination half-life of the drug from plasma of between 0.68 and 0.88 h over the 0.25-
20mgkg- range covered. There was no evident dose dependency over this range and studies with two
formulations showed mitozolomide to have good systemic availability when administered via the oral route (F
values of 0.66 and 0.81). The drug was also found to be systemically available when administered topically in
dimethylsulfoxide (F =0.47). Mitozolomide shows many biochemical and biological similarities to the
clinically used nitrosoureas BCNU and CCNU but our results show that it differs markedly in its kinetics
from these two agents, with mitozolomide having relatively sustained plasma levels. It is hoped that this may
be of therapeutic benefit if these levels are reflected in relative tumour concentrations.
Mitozolomide [CCRG 81010, M & B 39565, NSC
353451, 8-carbamoyl-3-(2-chloroethyl)imidazo[5, 1-
d]-1,2,3,5-tetrazin-4(3H)-one] is a new antitumour
agent possessing a novel chemical structure (Stevens
et al., 1984) which is currently undergoing Phase I
clinical evaluation in the UK. The drug was dis-
covered in our laboratories and screened against
the NCI murine tumour panel producing results
which compared favourably with those obtained for
a number of clinically used agents (Hickman
et al., 1985; 1982). In single dose studies, cures
(survival time in excess of 60 days) were seen
against L1210 and P388 leukemias at the optimally
active dose of 20mgkg-1 whilst prolonged survival
was also evident at the lower doses of 5 and
10mgkg- . Mechanistic studies (Stevens et al.,
1984; Gibson et al., 1984a, b; Horgan & Tisdale,
1983) have indicated that mitozolomide may be a
stable pro-drug form ofthe monochloroethyltriazene
MCTIC(5-[3-(2-chloroethyl)triazen-1-yl]imidazole-4-
carboxamide). Shealey had previously demonstrated
the activity of TIC-Mustard (NSC 82196, 5-[3,3-
Bis(2-chloroethyl)- I-triazen-1-yl]imidazole-4-car-
boxamide) against murine tumour models (Shealey
& Krauth, 1966) and postulated the role of MCTIC
in its mode of action (Shealey, 1975). However the
inherent chemical instability of MCTIC has preven-
ted its development as an agent in its own right.
Chemical decomposition studies indicated that
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mitozolomide decomposed with first order kinetics
in buffers at physiological pHs (t4 - 55min in
phosphate buffer pH 7.4, 37°C (Slack & Goddard,
1985). Rapid decomposition was apparent in basic
solutions but the drug was essentially stable under
acidic conditions. This paper reports the results of a
pharmacokinetic study conducted on male BALB/c
mice to determine the essential pharmacokinetic
parameters for the drug and to investigate its oral
bioavailability as a forerunner for a clinical
pharmacokinetic study forming part of the phase I
trial. The pharmacokinetics of transdermally
administered mitozolomide have also been
investigated.
Materials and methods
All experiments were conducted using male BALB/c
mice weighing - 25 g. Mitozolomide was generously
supplied by Dr E. Lunt of May & Baker Ltd.
(Dagenham, UK). All chemicals and solvents used
were of either analytical or chromatographic grade
and were used as supplied. A dose escalation study
was conducted using the i.p. route. The formulation
used was 10% dimethylsulphoxide (DMSO) in
saline (0.9%). The mitozolomide was dissolved in
DMSO prior to dilution with saline with an
injection volume of 0.2ml based on a 25g mouse
weight. Mice were also dosed orally with the same
formulation at a dose of 20mgkg-1. Additionally
mice were dosed both orally and i.p. at 20mgkg-1
with 0.2ml of a formulation consisting of mitozolo-
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mide in 10% DMSO in arachis oil. For the trans-
dermal study a small area (_1 cm2) on the back of
the animals was shaved on the day prior to dosing
and mice subsequently dosed at 20mgkg-1 by
layering 10il of a solution of mitozolomide in
DMSO onto the shaven area whilst the mice were
temporarily anaesthetized (nitrous oxide/halothane).
Blood samples were obtained at predetermined time
points by anaesthetizing the mice using a Boyle's
apparatus and removing 0.9ml of blood by cardiac
puncture. This was mixed with 0.1 ml of 3%
trisodium citrate solution (as an anticoagulant) and
immediately centrifuged. Supernatant plasma was
removed and stored frozen at -20°C, in the dark,
prior to analysis. Blood samples were taken at 0.25,
0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0 and 6.Oh post-dosing
in each case with between 4 and 7 mice being
evaluated at each time point. Additional 5min and
10min time points were included in the bio-
availability study at 20mgkg-1 for both the i.p.
and oral routes.
The HPLC method, previously described (Slack
et al., 1983, 1985), was employed for the
quantitative analysis of the plasma samples with 3-
(2-hydroxyethyl)-1,2,3-benzotriazin-4(3H)-one as
the internal standard. The method has a detection
limit of lOngml-1 and at the lowest dose studied
(0.25mgkg-1) plasma levels were well in excess of
this. Plasma levels were determined by comparing
peak area ratios to a calibration line generated by
at least 6 spiked standards. Values for kei were
estimated from the gradients generated by the linear
regression of plots of ln (concentration) vs. time
(slope= -kei). The AUC (area under the plasma
concentration time curve) values were estimated by
the trapezoidal method from 0-8 h in each case.
Other kinetic parameters were determined from the
following equations.
ti (elimination half-life)=0.693/ke,.
Clearance=Dose/AUC
Vd (volume ofdistribution) =clearance/kei.
F (Bioavailability)= AUC (i.p.)
Results and discussion
Screening studies (Hickman et al. 1985) had
identified the optimal antitumour dose for thera-
peutic activity in mice treated with mitozolomide to
be 20mgkg-1. Based on this the doses selected for
the i.p. dose escalation study were 0.25, 1.0, 5.0,
10.0 and 20.0mgkg-1.
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Figure 1 I.p. route dose escalation study. The data
are presented for 2 dose levels (20.0 and 1.Omgkg-1).
The lines represent a regression of the raw data
(pooled individual measurements from at least 2
separate experiments at each dose level) by the least
squares method using data from 0.25h onwards for
the 1.Omgkg-' dose and 0.18h onward for the
20mgkg-1 dose. The error bars indicate +1 s.d. of
the mean concentration at each time point. Similar
lines were obtained for the other 3 dose levels. (0)
20mgkg-1 i.p.; (0) I mgkg-1 i.p.
At all the dose levels investigated mitozolomide
was rapidly absorbed with no absorption or
distribution phase evident within the first 15min.
However, at 20mgkg-1 where 5 and 10min time
points were taken, mean plasma levels of 18.3 and
25.2mgl-1 respectively indicate an absorption
phase with peak plasma levels being reached
between 5 and 10min after dosing. Figure 1
summarises the results for the i.p. dose escalation
study. Correlation coefficients for the lines ranged
from 0.9414-0.9820 (with the exception of the
0.25mgkg-1 data which produced a lower value of
0.7755). On this basis the data was described by a
simple open one compartment model and Table I
summarises the kinetic parameters obtained using
this model. Consideration of the data for AUC and
peak plasma concentration with ascending dose
indicates that in both cases an approximately linear
relationship exists suggesting that mitozolomide
exhibits no apparent dose dependency over this
range. Figure 2 describes the data obtained from
the bioavailability study using the 10% DMSO inMITOZOLOMIDE PHARMACOKINETICS 39
Table I Pharmacokinetic parameters for mitozolomide
administered to mice (i.p.)
Maximum
plasma AUC
Dose ti (mgl11) (mg.hI-1)
(mgkg-) (h) concentrationa (0-8h) Vd (L)b
0.25 0.860 0.374 0.439 0.0176
1.0 0.681 1.152 1.201 0.0204
5.0 0.826 5.675 7.083 0.0210
10.0 0.884 9.824 11.618 0.0274
20.0 0.758 25.238 31.174 0.0173
aThis is the measured figure at to.25h (t0.18h for
20mg kg-').
bEvaluated on the basis of a mean mouse weight of 25g.
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Figure 2 Plot of mean concentration (mgl- ) versus
time (h) for the oral and i.p. doses using the
DMSO/saline formulation. Error bars indicate +±1 s.d.
of the mean concentration at each time point. (0)
20 mgkg -1 i.p.; (@) 20mgkg- I p.o.
saline formulation. A similar plot was obtained
with the 10% DMSO in arachis oil formulation
with respect to the drugs rapid absorption from the
oral formulation and its subsequent clearance with
the first order kinetics. However, the kinetic para-
meters and "F" values obtained did differ for the
two formulations. Using the saline/DMSO a mean
peak plasma level of 13.85mgl-1 was seen for the
oral route compared to the 25.24mgl-1 seen for
the i.p. route. The respective AUC values were
20.34mg.hl-1 and 31.17mg.hl-1 resulting in an F
value of 0.65 (F=AUC(PO)/AUC(i.p.)). In the case
of the arachis oil/DMSO formulation similar peak
plasma levels were obtained orally (13.16mgl-1)
but a lower level when dosing i.p. (16.31mgl-1).
However due to a longer plasma half-life (1.42h
versus 0.84h) the AUC values were higher
(27.15mg.hl-1 for the oral and 33.51mg.hl-1 for
the i.p.) and a higher F value of0.81 was obtained.
These oral studies, using two different
formulations, demonstrate that mitozolomide is
absorbed from the gastrointestinal tract both
rapidly and in significant quantities in mice. The
labile nature of the drug at pH values higher than
neutrality suggests that absorption probably occurs
via the stomach. The rapidity of the absorption
phase (with peak plasma levels being reached within
the first 15min using the DMSO/saline
formulation) and the subsequent similarity in the
elimination phase to that seen in the i.p. route show
that the oral route may present a viable means of
delivering the drug. The use of DMSO in
formulating mitozolomide suggested possibilities
with respect to topical administration since DMSO
has been shown to be a good transdermal carrier
(Wood & Wood, 1975): In addition Maddock et al.,
1966 had previously demonstrated the successful
use of transdermally applied cyclophosphamide,
using DMSO as the vehicle, in treating mouse
tumours. Figure 3 shows a comparison of the data
obtained from the transdermal study with the data
from the 20mgkg-1 i.p. experiment. Whilst it is
evident that plasma concentrations achieved
following the transdermal administration show
considerably more variation than the other two
dosage forms it is clear from a comparison of AUC
values (13.288 for the transdermal, 31.17 for the
i.p.) that significant amounts of the drug were
systemically available. This alternative means of
delivery may be of use against certain tumour
types.
It has been suggested that mitozolomide is a
stable pro-drug form of MCTIC and mode of
action studies comparing mitozolomide, MCTIC
and the chloroethylnitrosoureas (Gibson, 1984a, b)
have shown similarities in the degree and nature of
DNA cross-linking exhibited by these agents40 C. GODDARD et al.
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Figure 3 Plot of plasma concentration (mgI1) versus time (h). Error bars indicate +1 s.d. of the mean at
each time point. The F value (AUC(transdermal)/AUC (i.p.)) was 0.47. (0) 20mgkg1 i.p.; (0) 20mgkgt
transdermal.
against IMR-90 and VA-13 cell lines. Since mito-
zolomide produced similar screening results against
model tumours to those obtained by the nitro-
soureas it is interesting to note the contrast in the
pharmacokinetics of mitozolomide when compared
to those seen for the clinically used nitrosoureas
BCNU (carmustine) and CCNU (lomustine). Mito-
zolomide fits a single compartment model with
peak plasma concentrations of 25mgP- at the
optimal dose of 20mgkg- and an elimination
half-life of just under one hour. In both animals
and man (Levin et al., 1979, 1981) BCNU kinetics
are best described by a 2 compartment model with
plasma concentrations rapidly falling from an initial
peak such that in rat peak levels of -15mgl-1
following a dose of 14mgkg-1 had fallen to
1 mgl-1 within the first hour (in terms of AUC
the BCNU figure is -6.0mg.h -1 compared to
values of 11.6 and 31.2mg.h 1- for mitozolomide
at 10 and 20mgkg-1 respectively). Similarly, Lee &
Workman (1983) recently demonstrated that
CCNU pharmacokinetics in mice follow a similar
pattern. The plasma clearance of the nitrosoureas
was again biexponential with a rapid phase
preceding a slower phase. Peak concentrations of
7.5mgl-P following an i.p. dose of 20mgkg-1 had
fallen to 0.2mgl-1 within the first hour, with an
AUC of only 0.72mg.hl-1. Whilst much of this
effect may have been due, in the case of CCNU, to
metabolic hydroxylation of the cyclohexyl ring, the
total AUC for the four principal metabolites was
still only 7.88mg.hl-1, approximately one quarter
times that ofmitozolomide at the same dose.
These differences in kinetics, with mitozolomide
producing relatively sustained levels of parent drug,
may prove to be of therapeutic value if they reflect
a similarly high tumour concentration (Brindley &
Antoniw, 1984). On this basis results of the clinical
evaluation of mitozolomide are awaited with
considerable interest.
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